1. DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial. (25th January 2019) Authors: Danese, S; Sands, B E; O'Brien, C D; Zhang, H; Johanns, J; Sloan, S; Izanec, J; Szapary, P; Marano, C; Leong, R W; Rowbotham, D; Targan, S R; Van Assche, G Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S061 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. DOP55 Long-term outcomes after histologic-endoscopic mucosal healing: Results from the UNIFI study in Ulcerative Colitis. (21st January 2022) Authors: Leong, R; Sands, B; Peyrin-Biroulet, L; Marano, C; Miao, Y; Izanec, J; Feagan, B; Rubin, D Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i102 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P317 Characterisation of patients with delayed response to ustekinumab for Crohn's disease. (25th January 2019) Authors: Sands, B E; Oortwijn, A; Rijnders, N; Izanec, J; Gasink, C; Jacobstein, D; Adedokun, O J; Ma, T; Gao, L-L; Colombel, J-F; Targan, S; Ghosh, S; Sandborn, W J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S259 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. P347 New-onset autoimmune disorders, primarily psoriasis, in anti-TNF biologic exposed paediatric patients: the DEVELOP experience. (25th January 2019) Authors: Veereman, G; Griffiths, A; Colletti, R; Gold, B; Izanec, J; Busse, C; Wang, Y; Escher, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S276 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. P446 Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience. (25th January 2019) Authors: Escher, J; Dubinsky, M; Izanec, J; Busse, C; Wang, Y; Griffiths, A Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S334 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. P651 Disease severity and intensity of therapy predicts serious adverse events in paediatric ulcerative colitis: the DEVELOP experience. (25th January 2019) Authors: Winter, H; Izanec, J; Busse, C; Wang, Y; Hyams, J Journal: Journal of Crohn's and colitis Issue: Volume 13(2019)Supplement 1 Page Start: S445 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗